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Purpose/Objective: Notable radiosurgery (SRS) challenges in 
benign brain lesions are dose calculation accuracy and 
efficiency of the process (total time). The purpose of this 
work is to analyse our first year experience with RapidArc 
(RA) SRS patients treated at the TrueBeam STx (TB) linear 
accelerator. 
Materials and Methods: At our department patients 
undergoing SRS are treated in one single fraction with the 
Brainlab localization frame at TrueBeam.  
Initially, iPlan TPS was used to calculate dynamic conformal 
arc (DCA) plans. Once calculated, the plan was exported to 
Eclipse and prepared to treatment.  
To commission Eclipse (v 13) for SRS, main addressed topics 
were: spot sizes tuned to reproduce small field 
measurements (output for jaw sizes down to 1 cm x 1 cm and 
MLC fields down to 0.5 cm x 0.5 cm) as well as dosimetric 
leaf gap regarding RA calculations. iPlan plans were re-
calculated in Eclipse in order to obtain knowledge-based sets 
of constraints in the optimisation module and to get the best 
calculation parameters shortening the total planning time, 
giving the greatest accuracy achievable. The obtained dose 
distributions were compared against iPlan ones. 
The final process has been established as follows 
iPlan is used for segmentation, to allocate non-coplanar arcs 
(to take profit of previous experience and specificity of this 
TPS), and to generate Target positioners (Tapos). Plan is 
exported to Eclipse, structures a re-segmented as high 
resolution and help structures are defined to control fall-off 
doses. RA optimisation is performed with AAA algorithm (v13) 
using the intermediate dose calculation and jaw tracking 
options, 6MV and recently 6MV FFF are employed. After 
clinical plan approval, a verification plan is calculated on 
Octavius4D phantom. Verification is acquired with the 
1000SRS detector and analysed using 3D local gamma criteria 
(2%/2mm, 1%/1mm). If the verification criteria are met 
patient goes to treatment. Tapos are used to firstly position 
the patient and then a CBCT is acquired to obtain the final 
position (6D couch movements). 
Results for the commissioning comparisons and the first 
patients treated are presented, Paddick conformity index is 
reported. 
Results: A total of 45 benign lesions (schwanoma: 18; 
meningioma: 10; AVM: 7; acoustic neurinoma: 3; others: 7) 
have been treated at the TrueBeam, 10 with RA following the 
described process. 
The number of employed arcs ranged between 5 and 7. 
Sets of optimisation parameters have been obtained for each 
representative pathology allowing getting plan objectives in 
only one run. 
Most relevant planning involved times (minutes) are: 
preparation, about 15; optimisation/calculation, from 30 to 
50 (number of arcs, grid size, etc.); verification calculation, 
from 15 to 35. 
With RA the conformity index increases about 20% compared 
to DCA. 
Verifications mean gamma passing rates have been 99.6 
(2%/2mm) and 97.9 (1%/1mm). 
Conclusions: A feasible process has been described to treat 
SRS benign lesions with RapidArc. An adequate level of 
efficiency and accuracy is achieved. 
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Purpose/Objective: The Intra-Operative Radiation Therapy 
(IORT) is a specialized irradiation technique which allows a 
single high radiation dose (10 – 25 Gy) delivery during the 
surgical intervention, after the visible tumor resection. 
The choice of protecting shield materials is a compromise 
between the surgeon’s requirement to have it as thin as 
possible, as well as the necessity to totally absorb the 
primary radiation. The main aim of this work is to perform 
Monte Carlo simulation for IOERT beams with different 
shielding plates in place, and compare it with measurement 
to check dose in front of and behind the shielding plate. 
There are a few papers related to IORT but none of them 
focuses on shielding plate design. 
Materials and Methods: 
I.A. Monte Carlo Simulation 
The Mobetron 1000 head was modeled using the 
EGSnrc/BEAMnrc simulation package. The dose distribution in 
water for flat applicators was simulated with the DOSXYZnrc 
code, which scores dose in a water Phantom. This study is 
done for the most clinically used applicator (5.5 cm) with the 
maximum energy used of the accelerator (12MeV). Seven 
Mobetron components are modeled: electron source, first 
scattering foil, second scattering foil, fixed collimator #1 , 
ion monitor chamber, fixed collimator #2 and the patient 
applicator. It is necessary to validate Monte Carlo model 
against measurements (PDD, Profile ).  
A method to find the correct electron beam characteristics 
impinging on the scattering foil is to change iteratively some 
parameters and compare the simulations with measurements. 
We had to optimize the energy spectrum and the FWHM of 
the Gaussian source. 
I.B.Types of Shields studied  
There are many shield types used in different Mobetron 
centers. They are all composed of two materials: either 
PMMA/Cu, or Al/Pb or Al/Steel. All of them have been 
simulated with Monte Carlo and some of them have been 
measured with Radiochromic films. The shield was usually 
placed at the 90% isodose depth in water.  
Results: On figure 1, the matching between measured and 
calculated PDD and profiles is presented. On figure 2 there is 
an example of dose map distribution with an Al/Pb shield 
placed at 3.7cm depth. It is clear that there is no 
transmission and there is a significant backscattering effect 
close to the shield. Other types of shields gave similar results 
for transmission but slightly different results for 
backscattering. 
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Interestingly, we can use the backscattering effect to 
enhance the dose homogeneity in the target volume and a 
theoretical shield design will be presented.  
 
 
Figure 1: PDD & Profile measured curves and MC simulation  
 
 
Figure 2: Dose map for a Mobetron 12 MeV Beam, 5.5 cm 
Applicator and (Al/Pb) shield plate in water phantom 
 
Conclusions:  
- All of the studied shielding plates are clinically acceptable. 
Normally, the surgeon would prefer the thinnest shield 
(Al/Pb). 
- The good alignment of the applicator and the shield is a key 
issue  
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Purpose/Objective: Recent studies have warned about late 
toxicity, primarily cardiac toxicity, in patients diagnosed with 
breast cancer who have received radiation therapy. 
Although there are numerous publications and protocols 
there is no uniform recommendations for 3D radiation 
therapy for breast cancer about which are the best 
dose/volume constraints to evaluate this treatment. 
The purpose of this study is to quantify and compare 
different dose/volume constraints for the organs at risk 
(OARs) in breast cancer treatment based in the DVH of each 
study, in order to establish the most useful parameters to 
evaluate this type of treatment in our institution. 
Materials and Methods: 544 women were evaluated. Studies 
were grouped regarding the type of treatment (breast/chest 
wall, breast + boost, breast + regional nodal irradiation (RNI), 
breast+boost+RNI) and the fractionation scheme (2Gy or 
2.66Gy per fraction). 
Different dose/volume constraints for the heart and lung 
have been evaluated for each patient (Table 1). 
Also, for each patient the clinical pathology before and after 
the treatment has been evaluated. 
 
 
Results: From 544 patients only 2 developed symptomatic 
pulmonary complications and 4 patients developed cardiac 
complications probably related with the radiotherapy 
treatment.  
Regarding the dose/volume constraints: 
•For both lungs, V20Gy(16Gy*) <25% is achieved in about 97% 
of the patients. 
•For the ipsilateral lung, Dmean<17 Gy is achieved in more 
than 95% of the patients, except in treatments which 
includes the RNI, where only 64% meet the criteria. 
Furthermore, the criteria V30Gy<200cc is only achieved by 
33% of the patients, in the best situation (breast/chest wall 
hypofractionated) meanwhile for treatments which includes 
RNI only 9% meet the objective. For V20Gy<25% the results 
are in same direction as V30Gy<200cc. 
•For the heart, V30Gy(24Gy*)<30 cc is achieved by 29% of the 
patients in the best situation. V20Gy<10%, V40Gy<5% and 
V25Gy<10% is achieved by 45%, 41.4% and 52% in the best 
situations, meanwhile V45Gy<50% and V60Gy<30% is achieved 
by 100%.  
(*) value for hypofractionated treatments 
Conclusions: The type of treatment have a big influence in 
the percentage of cases that meet the dose/volume 
constraints. Treatments which include the RNI have a low 
percentage of achievements. 
According to our data, we can conclude that the 
V30(24)Gy<30cc for the heart and the V30(24)Gy<200cc for 
the ipsilateral lung are quite ambitious constraints and 
presents a strong dependency of the appearance of the RNI. 
Also, parameters as the V45Gy<33% , for the ipsilateral lung 
and V45Gy<50% for the heart, are very relaxed and the 
achievement of these constraints doesn’t mean that the plan 
would be an optimal plan. 
